Oct 24, 2023 7:00 am EDT NeoGenomics Announces the Commercial Availability of Two New Tests, Expanding Its Next-Generation Sequencing and Lung Cancer Portfolios
Oct 17, 2023 9:20 am EDT NeoGenomics to Report Third Quarter 2023 Financial Results on November 6, 2023
Jul 27, 2023 7:00 am EDT NeoGenomics Announces Medicare Coverage for RaDaR Assay for Minimal Residual Disease and Recurrence in Breast Cancer
Jul 18, 2023 7:10 am EDT NeoGenomics to Report Second Quarter 2023 Financial Results on August 8, 2023
Jun 29, 2023 7:00 am EDT NeoGenomics Expands Board of Directors with Appointments of Three Independent Directors
Jun 15, 2023 4:45 pm EDT NeoGenomics' RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage
Jun 5, 2023 7:00 am EDT NeoGenomics and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer
Jun 1, 2023 7:00 am EDT NeoGenomics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference
